{"id":1029,"date":"2021-07-01T13:58:37","date_gmt":"2021-07-01T13:58:37","guid":{"rendered":"http:\/\/debian-economist.eu\/wp\/?p=1029"},"modified":"2021-07-01T14:10:16","modified_gmt":"2021-07-01T14:10:16","slug":"1029","status":"publish","type":"post","link":"https:\/\/debian-economist.eu\/wp\/?p=1029","title":{"rendered":"L&rsquo;\u00e9quit\u00e9 mondiale en mati\u00e8re de vaccins exige une justice r\u00e9paratrice &#8211; pas de la charit\u00e9"},"content":{"rendered":"\n<div>\n<div>\n<p><strong><span style=\"letter-spacing: -0.004em;\">Ce billet est une traduction libre d&rsquo;un <a href=\"https:\/\/gh.bmj.com\/content\/6\/6\/e006504\" title=\"Global vaccine equity demands reparative justice \u2014 not charity\">\u00e9ditorial du British Journal of Medicine<\/a> sur l&rsquo;\u00e9quit\u00e9 mondiale dans l&rsquo;acc\u00e8s \u00e0 la vaccination contre le Covid 19.&nbsp;<\/span><\/strong><\/p>\n<\/div>\n<div>\n<h1>L&rsquo;\u00e9quit\u00e9 mondiale en mati\u00e8re de vaccins exige une justice r\u00e9paratrice &#8211; pas de la charit\u00e9&nbsp;<\/h1>\n<\/div>\n<div>\n<div>\n<p><span>Sophie Harman<\/span><a href=\"#aff-1\"><sup>1<\/sup><\/a>, <span style=\"letter-spacing: -0.004em;\">Parsa Erfani<\/span><a href=\"#aff-2\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>2<span style=\"letter-spacing: -0.004em;\">,<\/span><\/sup><\/a><a href=\"#aff-3\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>3<\/sup><\/a><span style=\"letter-spacing: -0.004em;\">, <\/span><span style=\"letter-spacing: -0.004em;\">Tinashe Goronga<\/span><a href=\"#aff-4\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>4<\/sup><\/a><span style=\"letter-spacing: -0.004em;\">, <\/span><span style=\"letter-spacing: -0.004em;\">Jason Hickel<\/span><a href=\"#aff-5\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>5<\/sup><\/a><span style=\"letter-spacing: -0.004em;\">, <\/span><span style=\"letter-spacing: -0.004em;\">Michelle Morse<a href=\"#aff-2\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>2,<\/sup><\/a><\/span><a href=\"#aff-6\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>6<\/sup><\/a><a href=\"#aff-6\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><\/a><span style=\"letter-spacing: -0.004em;\">,<\/span><a href=\"#aff-7\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>7<\/sup><\/a><span style=\"letter-spacing: -0.004em;\">, <\/span><a href=\"http:\/\/orcid.org\/0000-0001-8437-0671\"><\/a><span>Eugene T Richardson<a href=\"#aff-2\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>2<span style=\"letter-spacing: -0.004em;\">,<\/span><\/sup><\/a><a href=\"#aff-2\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><\/a><a href=\"#aff-6\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\">6<\/a><\/span><\/p>\n<p><a><\/a><\/p>\n<address><sup>1<\/sup><span>Politics and International Relations<\/span>, <span>Queen Mary University of London<\/span>, <span>London<\/span>, UK<\/address>\n<p><a><\/a><\/p>\n<address><sup>2<\/sup><span>Department of Global Health and Social Medicine<\/span>, <span>Harvard Medical School<\/span>, <span>Boston<\/span>, <span>Massachusetts<\/span>, USA<\/address>\n<p><a><\/a><\/p>\n<address><sup>3<\/sup><span>University of Global Health Equity<\/span>, <span>Butaro<\/span>, Rwanda<\/address>\n<p><a><\/a><\/p>\n<address><sup>4<\/sup><span>Centre for Health Equity Zimbabwe<\/span>, <span>Harare<\/span>, Zimbabwe<\/address>\n<p><a><\/a><\/p>\n<address><sup>5<\/sup><span>Department of Anthropology<\/span>, <span>London School of Economics<\/span>, <span>London<\/span>, UK<\/address>\n<p><a><\/a><\/p>\n<address><sup>6<\/sup><span>Department of Medicine<\/span>, <span>Brigham and Women&rsquo;s Hospital<\/span>, <span>Boston<\/span>, <span>Massachusetts<\/span>, USA<\/address>\n<p><a><\/a><\/p>\n<address><sup>7<\/sup><span>New York City Department of Health and Mental Hygiene<\/span>, <span>New York<\/span>, <span>NY<\/span>, USA<\/address>\n<p><span>Correspondance avec le<\/span> Dr Eugene T Richardson<\/p>\n<\/div>\n<div><\/div>\n<div>\n<div>\n<div>\n<h2>Introduction<\/h2>\n<p>\u00c0 la fin du mois d&rsquo;avril, plus de 80 % des vaccins COVID-19 dans le monde avaient \u00e9t\u00e9 administr\u00e9s \u00e0 des personnes vivant dans des pays riches, et seulement 0,3 % \u00e0 des personnes vivant dans des pays \u00e0 faible revenu.<a href=\"#ref-1\"><sup>1<\/sup><\/a> Ce d\u00e9s\u00e9quilibre d\u00e9plorable n&rsquo;est pas le fruit du hasard. Les pays \u00e0 haut revenu ont utilis\u00e9 leur pouvoir de n\u00e9gociation n\u00e9ocolonial, leur influence sur la politique mondiale et leur capital pour obtenir suffisamment de doses pour couvrir 245 % de leurs citoyens, tout en laissant peu de doses aux pays plus pauvres.<a href=\"#ref-2\"><sup>2<\/sup><\/a> En cons\u00e9quence, les pays \u00e0 faible revenu pourraient ne pas \u00eatre en mesure de vacciner leurs populations avant 2023.<a href=\"#ref-3\"><sup>3<\/sup><\/a><\/p>\n<p>Cette in\u00e9galit\u00e9 est un nouvel exemple de la mani\u00e8re dont les int\u00e9r\u00eats du capitalisme racial font fi de la r\u00e8gle d&rsquo;or de la solidarit\u00e9 mondiale &#8211; privil\u00e9gier le risque le plus \u00e9lev\u00e9.<a href=\"#ref-4\"><sup>4<\/sup><\/a> Actuellement, les personnes \u00e2g\u00e9es et m\u00e9dicalement vuln\u00e9rables meurent du COVID-19 de mani\u00e8re disproportionn\u00e9e dans les pays pauvres, tandis que les personnes jeunes et en bonne sant\u00e9 se font vacciner dans les pays riches.<a href=\"#ref-5\"><sup>5<\/sup><\/a> L&rsquo;apartheid vaccinal n&rsquo;est pas un ph\u00e9nom\u00e8ne nouveau. L&rsquo;id\u00e9e que seuls certains coins du monde puissent b\u00e9n\u00e9ficier de traitements qui sauvent des vies est une r\u00e9alit\u00e9 quotidienne d&rsquo;un syst\u00e8me de sant\u00e9 mondial r\u00e9gi par un mod\u00e8le capitaliste et philanthropique.<a href=\"#ref-6\"><sup>6 7<\/sup><\/a> Mais en p\u00e9riode de crise &#8211; et alors que de nouveaux variants menacent les plans de vaccination des pays riches &#8211; ces in\u00e9galit\u00e9s et leurs solutions sont au c\u0153ur du d\u00e9bat mondial.<a href=\"#ref-8\"><sup>8<\/sup><\/a><\/p>\n<div>\n<div>\n<div><\/div>\n<\/div>\n<\/div>\n<p>Les responsables politiques des pays riches sont conscients de ces probl\u00e8mes. Mais les solutions qu&rsquo;ils ont propos\u00e9es jusqu&rsquo;\u00e0 pr\u00e9sent ne s&rsquo;attaquent en rien aux probl\u00e8mes structurels sous-jacents. Ils proposent des dons de charit\u00e9 et des solutions partielles et temporaires destin\u00e9es \u00e0 d\u00e9tourner les demandes de r\u00e9forme substantielles pour lesquelles les pays du Sud se battent, notamment la remise en cause des r\u00e9gimes de propri\u00e9t\u00e9 intellectuelle (PI) contraires \u00e0 l&rsquo;\u00e9thique.<a href=\"#ref-9\"><sup>9<\/sup><\/a> Cette approche ne fonctionnera pas, car elle n&rsquo;est pas con\u00e7ue pour \u00ab\u00a0fonctionner\u00a0\u00bb. Si nous voulons mettre fin \u00e0 l&rsquo;apartheid vaccinal, nous devons nous attaquer aux causes profondes des in\u00e9galit\u00e9s mondiales en mati\u00e8re de sant\u00e9. Nous avons besoin d&rsquo;une justice r\u00e9paratrice.<\/p>\n<\/div>\n<div>\n<h2>Trois \u00ab\u00a0solutions\u00a0\u00bb limit\u00e9es \u00e0 l&rsquo;in\u00e9galit\u00e9 en mati\u00e8re de vaccination<\/h2>\n<p>Il existe actuellement trois approches pour r\u00e9duire l&rsquo;in\u00e9galit\u00e9 dans la distribution du vaccin COVID-19 : la charit\u00e9 bilat\u00e9rale, la charit\u00e9 multilat\u00e9rale et les d\u00e9rogations ou suspensions temporaires de la propri\u00e9t\u00e9 intellectuelle.<\/p>\n<p>La premi\u00e8re est la plus simple. Les Etats qui stockent des vaccins COVID-19 se sont engag\u00e9s \u00e0 partager leurs reliquats avec les pays \u00e0 revenu faible ou interm\u00e9diaire. La Norv\u00e8ge a \u00e9t\u00e9 l&rsquo;une des premi\u00e8res nations \u00e0 accepter de donner des doses aux pays les plus pauvres, parall\u00e8lement \u00e0 son programme de vaccination<span style=\"letter-spacing: -0.004em;\">.<\/span><a href=\"#ref-10\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>10<\/sup><\/a><span style=\"letter-spacing: -0.004em;\"> Il s&rsquo;agit de la forme d&rsquo;\u00e9quit\u00e9 la plus faible, car on ne sait pas si les vaccins seront fournis gratuitement, \u00e0 moindre co\u00fbt, s&rsquo;ils seront li\u00e9s \u00e0 la diplomatie ou \u00e0 la conditionnalit\u00e9, ni, surtout, quand ils seront disponibles, o\u00f9 ils iront ou combien ils seront fournis. L&rsquo;approche caritative bilat\u00e9rale a peu \u00e0 voir avec l&rsquo;\u00e9quit\u00e9 et davantage avec la g\u00e9opolitique, la richesse et la d\u00e9pendance \u00e0 l&rsquo;aide.<\/span><a href=\"#ref-11\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>11 12<\/sup><\/a><\/p>\n<p>TLa seconde est la charit\u00e9 multilat\u00e9rale, dont COVAX est le meilleur exemple. En 2020, le COVAX est n\u00e9 d&rsquo;une collaboration internationale entre l&rsquo;Organisation mondiale de la sant\u00e9 (OMS), le Fonds des Nations unies pour l&rsquo;enfance, Gavi et la Coalition for Epidemic Preparedness Innovations pour garantir un acc\u00e8s mondial \u00e9quitable aux vaccins COVID-19.<a href=\"#ref-13\"><sup>13 <\/sup><\/a>Les pays riches peuvent obtenir des doses pour 10 \u00e0 50 % de leur population, en fonction du montant qu&rsquo;ils ont vers\u00e9, et les pays pauvres peuvent obtenir des doses pour 20 % de leur population gr\u00e2ce \u00e0 ce syst\u00e8me. Ce sont les 20 % pour les pays pauvres qui sont devenus l&rsquo;argument de vente unique de COVAX : il s&rsquo;agit d&rsquo;un m\u00e9canisme qui garantit que chaque pays du monde peut recevoir le vaccin, quelle que soit sa capacit\u00e9 de paiement. C&rsquo;est la premi\u00e8re fois qu&rsquo;une telle initiative est test\u00e9e.<\/p>\n<p><\/p>\n<p>Les lacunes du COVAX sont nombreuses. Si les vaccins sont livr\u00e9s comme pr\u00e9vu, le COVAX pourrait atteindre 27 % de la population des pays \u00e0 faible revenu d&rsquo;ici la fin de 2021 &#8211; un objectif d\u00e9primant par rapport \u00e0 la couverture estim\u00e9e \u00e0 70 % n\u00e9cessaire \u00e0 l&rsquo;immunit\u00e9 collective et au libre acc\u00e8s aux vaccins actuellement accord\u00e9 aux Am\u00e9ricains.<a href=\"#ref-14\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>14 15 <\/sup><\/a><span style=\"letter-spacing: -0.004em;\"><\/span>En outre, le COVAX est encore largement sous-financ\u00e9 et les cha\u00eenes d&rsquo;approvisionnement suscitent des inqui\u00e9tudes.<\/p>\n<p><\/p>\n<p>Si le transfert de capitaux et de ressources des pays riches vers les pays plus pauvres est certainement n\u00e9cessaire dans la r\u00e9ponse actuelle \u00e0 la pand\u00e9mie, tout syst\u00e8me reposant uniquement sur l&rsquo;aide ne parviendra pas \u00e0 atteindre l&rsquo;\u00e9quit\u00e9. Dans un contexte de p\u00e9nurie de vaccins, o\u00f9 les fournisseurs ne sont pas en mesure de livrer les doses comme pr\u00e9vu et o\u00f9 les pays interdisent les exportations pour conserver les vaccins chez eux, les pays b\u00e9n\u00e9ficiaires de l&rsquo;aide COVAX risquent de tomber plus bas sur la liste des priorit\u00e9s, en attendant les vaccins restants des stocks des pays riches.<span style=\"letter-spacing: -0.004em;\"><\/span><a href=\"#ref-16\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>16\u201318<\/sup><\/a><\/p>\n<p><\/p>\n<p>Mais le plus pernicieux dans le syst\u00e8me COVAX, c&rsquo;est que les pays riches et leurs entreprises pharmaceutiques l&rsquo;ont utilis\u00e9 \u00e0 plusieurs reprises comme un bouclier pour d\u00e9tourner les demandes d&rsquo;exemption de propri\u00e9t\u00e9 intellectuelle. Il s&rsquo;agit l\u00e0 d&rsquo;un probl\u00e8me r\u00e9current de l&rsquo;aide : elle recouvre et d\u00e9tourne notre attention de la violence structurelle sous-jacente. Et ce faisant, elle maintient et perp\u00e9tue les in\u00e9galit\u00e9s. Il y a plus de 50 ans, Kwame Nkrumah a observ\u00e9 que l&rsquo;aide est un \u00ab\u00a0cr\u00e9dit renouvelable\u00a0\u00bb qui revient aux pays du Nord sous la forme de profits accrus.<a href=\"#ref-19\"><sup>19<\/sup><\/a> Dans la mesure o\u00f9 le COVAX est utilis\u00e9 pour prot\u00e9ger les brevets et les profits des entreprises, les paroles de Nkrumah restent d&rsquo;actualit\u00e9.<\/p>\n<p><\/p>\n<p>La troisi\u00e8me approche est ax\u00e9e sur la mise en commun, les d\u00e9rogations temporaires ou la suspension de la PI. En mai 2020, l&rsquo;OMS a cr\u00e9\u00e9 le pool d&rsquo;acc\u00e8s aux technologies COVID-19 pour que les entreprises puissent partager la PI et transf\u00e9rer les technologies de mani\u00e8re coordonn\u00e9e. Mais \u00e0 ce jour, aucune entreprise n&rsquo;a utilis\u00e9 le processus de transfert &#8211; probablement parce que de telles formes de partage mondial de la PI r\u00e9duiraient les b\u00e9n\u00e9fices, m\u00eame si des redevances sont incluses.<a href=\"#ref-20\"><sup>20 <\/sup><\/a>Les entreprises pharmaceutiques et les universit\u00e9s pr\u00e9f\u00e8rent les accords de transfert ponctuels car ils leur permettent de fixer leurs propres conditions avec des accords de non-divulgation. \u00c9tant donn\u00e9 qu&rsquo;elles doivent rendre des comptes aux actionnaires et aux conseils d&rsquo;administration, et non aux patients, ce sont les incitations financi\u00e8res qui d\u00e9terminent les d\u00e9cisions de transfert, et non la demande de sant\u00e9 publique.<\/p>\n<p><\/p>\n<p>Apr\u00e8s les blocages de l&rsquo;OMS en mati\u00e8re de propri\u00e9t\u00e9 intellectuelle, l&rsquo;attention s&rsquo;est port\u00e9e sur l&rsquo;Organisation mondiale du commerce (OMC). En octobre 2020, l&rsquo;Inde et l&rsquo;Afrique du Sud ont propos\u00e9 une renonciation temporaire aux droits de PI sur les technologies COVID-19 pour la dur\u00e9e de la pand\u00e9mie, afin que tous les fabricants disposant de capacit\u00e9s suffisantes et d&rsquo;un savoir-faire partag\u00e9 puissent lancer la production.<a href=\"#ref-21\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>21<\/sup><\/a><span style=\"letter-spacing: -0.004em;\"> Bien que soutenue par plus de 100 pays au sein de l&rsquo;OMC et par une campagne mondiale en faveur du \u00ab\u00a0vaccin du peuple\u00a0\u00bb, la proposition a \u00e9t\u00e9 bloqu\u00e9e \u00e0 plusieurs reprises \u00e0 chaque r\u00e9union du comit\u00e9 depuis lors par certains pays riches dot\u00e9s d&rsquo;importantes industries pharmaceutiques, notamment le Royaume-Uni, le Japon et les \u00c9tats de l&rsquo;UE.<\/span><a href=\"#ref-22\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>22 23<\/sup><\/a><\/p>\n<p><\/p>\n<p>Ceux qui s&rsquo;opposent \u00e0 la renonciation \u00e0 la propri\u00e9t\u00e9 intellectuelle font valoir qu&rsquo;elle ne r\u00e9soudra en rien le probl\u00e8me : m\u00eame si l&rsquo;on lib\u00e9rait la recette des vaccins, les pays \u00e0 revenu faible ou interm\u00e9diaire n&rsquo;ont pas la capacit\u00e9 de les produire.<a href=\"#ref-24\"><sup>24<\/sup><\/a> Mais cet argument est sp\u00e9cieux. Tout d&rsquo;abord, plusieurs pays \u00e0 revenu interm\u00e9diaire, dont l&rsquo;Inde, le Br\u00e9sil, le S\u00e9n\u00e9gal et l&rsquo;Afrique du Sud, ont la capacit\u00e9 d&rsquo;augmenter leur production en r\u00e9affectant les capacit\u00e9s de production existantes.<a href=\"#ref-25\"><sup>25 <\/sup><\/a>En outre, une renonciation \u00e0 la propri\u00e9t\u00e9 intellectuelle peut et doit \u00eatre compl\u00e9t\u00e9e par des transferts de technologie, un soutien logistique et un investissement financier pour faciliter ce processus de reconversion. Et le point le plus important est qu&rsquo;une telle d\u00e9rogation pourrait r\u00e9duire consid\u00e9rablement les co\u00fbts de mani\u00e8re g\u00e9n\u00e9rale, rendant les importations de vaccins plus abordables pour les pays pauvres.<\/p>\n<p><\/p>\n<p>Les opposants \u00e0 la d\u00e9rogation affirment \u00e9galement que les obstacles li\u00e9s \u00e0 la propri\u00e9t\u00e9 intellectuelle peuvent \u00eatre r\u00e9solus par les dispositions existantes en mati\u00e8re de \u00ab\u00a0licences obligatoires\u00a0\u00bb dans le cadre de l&rsquo;accord de l&rsquo;OMC sur les aspects des droits de propri\u00e9t\u00e9 intellectuelle qui touchent au commerce (ADPIC).<a href=\"#ref-26\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>26<\/sup><\/a><span style=\"letter-spacing: -0.004em;\"> Mais l&rsquo;exp\u00e9rience montre que ce processus est lent, lourd et sujet \u00e0 diverses pratiques de d\u00e9nigrement de la part de la communaut\u00e9 internationale.<\/span><a href=\"#ref-27\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>27 28<\/sup><\/a><span style=\"letter-spacing: -0.004em;\"> Certains \u00e9voquent plut\u00f4t la possibilit\u00e9 de licences volontaires. Mais les licences volontaires sont souvent ex\u00e9cut\u00e9es en secret et sont limit\u00e9es aux entreprises ou aux gouvernements qui en ont les moyens. L&rsquo;universit\u00e9 de Pennsylvanie, qui d\u00e9tient les droits de propri\u00e9t\u00e9 intellectuelle relatifs aux vaccins \u00e0 ARNm, aide l&rsquo;universit\u00e9 Chulalongkorn de Bangkok \u00e0 d\u00e9velopper une installation de production de vaccins. Ce partenariat a \u00e9t\u00e9 possible parce que la Tha\u00eflande, contrairement \u00e0 d&rsquo;autres pays \u00e0 revenu interm\u00e9diaire, a pu mettre de l&rsquo;argent \u00e0 disposition.<\/span><a href=\"#ref-29\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>29<\/sup><\/a><span style=\"letter-spacing: -0.004em;\"> Les pays les plus pauvres sont laiss\u00e9s pour compte. Le partage de la propri\u00e9t\u00e9 intellectuelle et les transferts de technologie peuvent et vont acc\u00e9l\u00e9rer la production mondiale de vaccins. La question est de savoir \u00e0 quelles conditions. Des organisations telles que l&rsquo;OMS et l&rsquo;Union africaine mobilisent actuellement un soutien et des ressources pour acc\u00e9l\u00e9rer la production dans les pays \u00e0 revenu faible ou interm\u00e9diaire.<\/span><a href=\"#ref-30\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>30 31<\/sup><\/a><span style=\"letter-spacing: -0.004em;\"> Mais ces efforts seront vains si la propri\u00e9t\u00e9 intellectuelle des technologies COVID-19 n&rsquo;est pas partag\u00e9e largement et rapidement.<\/span><\/p>\n<\/div>\n<div>\n<h2>La colonialisme vaccinal<\/h2>\n<p>Les approches de l&rsquo;\u00e9quit\u00e9 vaccinale bas\u00e9es sur les donateurs sont fond\u00e9es sur des id\u00e9es anciennes, voire coloniales, d&rsquo;aide et de d\u00e9pendance, qui n&rsquo;ont pas r\u00e9ussi \u00e0 r\u00e9pondre aux besoins sanitaires du monde majoritaire ni \u00e0 assurer l&rsquo;\u00e9quit\u00e9 sanitaire. Ce mod\u00e8le rat\u00e9 n&rsquo;a pas favoris\u00e9 l&rsquo;\u00e9quit\u00e9 en mati\u00e8re de sant\u00e9 dans le pass\u00e9 et est clairement inad\u00e9quat dans le pr\u00e9sent, en raison de la d\u00e9pendance \u00e0 l&rsquo;\u00e9gard des caprices des donateurs (l&rsquo;approche bilat\u00e9rale des \u00ab\u00a0restes\u00a0\u00bb), des lacunes et insuffisances persistantes en mati\u00e8re de financement (COVAX), ainsi que de la diplomatie et de l&rsquo;obstruction qui prennent beaucoup de temps pour d\u00e9terminer ce qui rel\u00e8ve ou non des r\u00e8gles commerciales actuelles (OMC).<\/p>\n<p><br>Une fois encore, dans l&rsquo;\u00e9conomie politique de la sant\u00e9 mondiale, le mod\u00e8le caritatif du COVAX devient l&rsquo;\u00e9cran de fum\u00e9e de syst\u00e8mes in\u00e9quitables. Lorsqu&rsquo;on interroge les \u00c9tats sur leurs stocks, ils citent le COVAX. Lorsqu&rsquo;on interroge les entreprises pharmaceutiques sur leur propri\u00e9t\u00e9 intellectuelle, elles citent COVAX ou leur engagement \u00e0 faible co\u00fbt. L&rsquo;accent mis sur un mod\u00e8le d&rsquo;aide bas\u00e9 sur les donateurs pour atteindre l&rsquo;\u00e9quit\u00e9 en mati\u00e8re de vaccins a d\u00e9tourn\u00e9 les dirigeants des id\u00e9ologies, des syst\u00e8mes \u00e9conomiques et des r\u00e9glementations commerciales qui laissent l&rsquo;acc\u00e8s aux m\u00e9dicaments aux forces du march\u00e9 plut\u00f4t qu&rsquo;aux priorit\u00e9s de la sant\u00e9 mondiale.<a href=\"#ref-32\" style=\"background-color: #ffffff; letter-spacing: -0.004em;\"><sup>32<\/sup><\/a><span style=\"letter-spacing: -0.004em;\">&nbsp;<\/span><\/p>\n<p>Pour parvenir \u00e0 une justice vaccinale mondiale, il faut une \u00e9volution rapide des r\u00e9glementations commerciales et de la transparence des contrats, afin de rationaliser le partage de la propri\u00e9t\u00e9 intellectuelle et les transferts de technologie. Les collaborations entre \u00e9conomies qui en r\u00e9sulteront permettront non seulement d&rsquo;acc\u00e9l\u00e9rer la production de vaccins, mais aussi d&rsquo;accro\u00eetre la concurrence et de faire baisser les prix des vaccins.<\/p>\n<p><\/p>\n<p>Enfin, les anciens mod\u00e8les d&rsquo;\u00e9quit\u00e9 vaccinale n&rsquo;ont pas suivi l&rsquo;\u00e9volution du discours et de la r\u00e9flexion sur la gouvernance, l&rsquo;\u00e9quit\u00e9 et la justice en mati\u00e8re de sant\u00e9 mondiale. 2021 n&rsquo;est pas le d\u00e9but des ann\u00e9es 2000, o\u00f9 de nouveaux partenariats public-priv\u00e9 ou mod\u00e8les de financement \u00e9taient de rigueur. Les pays donateurs se m\u00e9fient de plus en plus de la d\u00e9pendance \u00e0 l&rsquo;\u00e9gard de l&rsquo;aide, car ils doivent payer le co\u00fbt de la poursuite de programmes de sant\u00e9 tr\u00e8s m\u00e9diatis\u00e9s dont le rendement strat\u00e9gique diminue. Les pays b\u00e9n\u00e9ficiaires de l&rsquo;aide sont \u00e9galement exasp\u00e9r\u00e9s par les d\u00e9ficits de financement qui entra\u00eenent des retards et des p\u00e9nuries de mat\u00e9riel, par le complexe industriel des ONG et les consultants qui les rationalisent, et, fondamentalement, par l&rsquo;id\u00e9e que leurs populations ne semblent compter que lorsqu&rsquo;un autre \u00c9tat peut en tirer profit.<\/p>\n<\/div>\n<div>\n<h2>Conclusion<\/h2>\n<p>L&rsquo;apartheid vaccinal n&rsquo;est qu&rsquo;un sympt\u00f4me des in\u00e9galit\u00e9s sanitaires mondiales plus larges qui trouvent leurs racines dans le colonialisme et persistent aujourd&rsquo;hui en raison des formes n\u00e9ocoloniales de pouvoir. Comme l&rsquo;\u00e9crit Grosfoguel, \u00ab\u00a0les structures mondiales h\u00e9t\u00e9rog\u00e8nes et multiples mises en place sur une p\u00e9riode de 450 ans ne se sont pas \u00e9vapor\u00e9es avec la d\u00e9colonisation juridico-politique de la p\u00e9riph\u00e9rie au cours des 50 derni\u00e8res ann\u00e9es. Nous continuons \u00e0 vivre sous la m\u00eame \u00ab\u00a0matrice de pouvoir colonial\u00a0\u00bb. Avec la d\u00e9colonisation juridico-politique, nous sommes pass\u00e9s d&rsquo;une p\u00e9riode de \u00ab\u00a0colonialisme mondial\u00a0\u00bb \u00e0 la p\u00e9riode actuelle de \u00a0\u00bb colonialisme mondial \u00ab\u00a0.<a href=\"#ref-33\"><sup>33<\/sup><\/a><\/p>\n<p><\/p>\n<p>La justice en mati\u00e8re de vaccins commence par le d\u00e9passement des mod\u00e8les d&rsquo;aide au don de vaccins, dans lesquels les pays les plus pauvres se voient offrir les restes de vaccins. Il s&rsquo;agit de parvenir rapidement \u00e0 un consensus mondial sur la renonciation \u00e0 la propri\u00e9t\u00e9 intellectuelle, de d\u00e9mocratiser la propri\u00e9t\u00e9 intellectuelle et le savoir-faire en mati\u00e8re de vaccins et d&rsquo;aider les pays \u00e0 faible et moyen revenu \u00e0 renforcer leurs capacit\u00e9s de production pour cette pand\u00e9mie et la prochaine. Ces mesures peuvent marquer le d\u00e9but d&rsquo;un mouvement de justice r\u00e9paratrice dans le domaine de la sant\u00e9 mondiale, qui exige que nous affrontions et renversions les h\u00e9ritages coloniaux qui continuent de d\u00e9vaster la sant\u00e9 des pays \u00e0 revenu faible et interm\u00e9diaire.<a href=\"#ref-34\"><sup>34<\/sup><\/a> Un engagement \u00e0 financer la justice vaccinale face \u00e0 la pand\u00e9mie de COVID-19 peut \u00eatre un premier pas dans cette direction.<\/p>\n<p><\/p>\n<\/div>\n<div>\n<div>\n<p><span style=\"color: inherit; inherit;font-size: 18pt; letter-spacing: -0.004em;\">Bibliographie<\/span><\/p>\n<\/div>\n<\/div>\n<div>\n<ol class=\"cit-list\">\n<li><a href=\"#xref-ref-1-1\" title=\"View reference 1 in text\">1.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Ghebreyesus<\/span> <span>TA<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>I run the WHO and i know that rich countries must make a choice [Internet]. The New York Times<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.nytimes.com\/2021\/04\/22\/opinion\/who-covid-vaccines.html\">https:\/\/www.nytimes.com\/2021\/04\/22\/opinion\/who-covid-vaccines.html<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-2-1\" title=\"View reference 2 in text\">2.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>KFF<\/span><\/li>\n<\/ol>\n<cite>. <span>Global COVID-19 vaccine access: a snapshot of inequality [Internet]<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.kff.org\/policy-watch\/global-covid-19-vaccine-access-snapshot-of-inequality\/\">https:\/\/www.kff.org\/policy-watch\/global-covid-19-vaccine-access-snapshot-of-inequality\/<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-3-1\" title=\"View reference 3 in text\">3.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>The Economist<\/span><\/li>\n<\/ol>\n<cite>. <span>More than 85 poor countries will not have widespread access to coronavirus vaccines before 2023 &#8211; Economist Intelligence Unit [Internet]<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.eiu.com\/n\/85-poor-countries-will-not-have-access-to-coronavirus-vaccines\/\">https:\/\/www.eiu.com\/n\/85-poor-countries-will-not-have-access-to-coronavirus-vaccines\/<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-4-1\" title=\"View reference 4 in text\">4.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Robinson<\/span> <span>CJ<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>Black Marxism<\/span>. <span>University of North Carolina Press<\/span>, <span>1983<\/span>.<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-5-1\" title=\"View reference 5 in text\">5.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>African COVID-19 Critical Care Outcomes Study (ACCCOS) Investigators<\/span><\/li>\n<\/ol>\n<cite>. <span>Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study<\/span>. <abbr class=\"cit-jnl-abbrev\">Lancet<\/abbr> <span>2021<\/span>;<span>397<\/span>:<span>1885<\/span>\u2013<span>94<\/span>.<a href=\"http:\/\/dx.doi.org\/10.1016\/S0140-6736(21)00441-4\">doi:10.1016\/S0140-6736(21)00441-4<\/a><span><span>pmid:<\/span>http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34022988<\/span><\/cite><\/div>\n<div><a href=\"https:\/\/justpaste.it\/%7Bopenurl%7D?query=rft.jtitle%253DLancet%26rft.volume%253D397%26rft.spage%253D1885%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\"><span>OpenUrl<\/span><\/a><a href=\"https:\/\/justpaste.it\/lookup\/external-ref?access_num=http:\/\/www.n&amp;link_type=MED&amp;atom=%2Fbmjgh%2F6%2F6%2Fe006504.atom\"><span>PubMed<\/span><\/a><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-6-1\" title=\"View reference 6 in text\">6.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Richardson<\/span> <span>ET<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>Epidemic illusions: on the coloniality of global public health<\/span>. <span>The MIT Press<\/span>, <span>2020<\/span>.<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-6-1\" title=\"View reference 7 in text\">7.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>\u017di\u017eek<\/span> <span>S<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>Violence?: six sideways reflections. Picador<\/span>, <span>2008<\/span>.<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-8-1\" title=\"View reference 8 in text\">8.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>BBC News<\/span><\/li>\n<\/ol>\n<cite>. <span>Covid-19 variants pose \u201creal threat\u201d to vaccine progress, CDC warns [Internet].<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.bbc.com\/news\/world-us-canada-56247656\">https:\/\/www.bbc.com\/news\/world-us-canada-56247656<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-9-1\" title=\"View reference 9 in text\">9.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Hassan<\/span> <span>F<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>Drug Companies and Rich Countries Are Creating a System of Vaccine Apartheid [Internet]. Foreign Policy<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/foreignpolicy.com\/2021\/02\/23\/dont-let-drug-companies-create-a-system-of-vaccine-apartheid\/\">https:\/\/foreignpolicy.com\/2021\/02\/23\/dont-let-drug-companies-create-a-system-of-vaccine-apartheid\/<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-10-1\" title=\"View reference 10 in text\">10.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Rigby<\/span> <span>J<\/span><\/span>,<\/li>\n<li><span><span>Newey<\/span> <span>S<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>Norway to share Covid-19 vaccine with poorer countries at same time as protecting its own citizens [Internet]. The Telegraph<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.telegraph.co.uk\/global-health\/science-and-disease\/norway-share-covid-19-vaccine-poorer-countries-time-protecting\/\">https:\/\/www.telegraph.co.uk\/global-health\/science-and-disease\/norway-share-covid-19-vaccine-poorer-countries-time-protecting\/<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-11-1\" title=\"View reference 11 in text\">11.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Rodney<\/span> <span>W<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>How Europe underdeveloped Africa<\/span>. <span>Bogle-L\u2019Ouverture Publications<\/span>, <span>1972<\/span>.<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-11-1\" title=\"View reference 12 in text\">12.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Gunder Frank<\/span> <span>A<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>The development of Underdevelopment<\/span>. <abbr class=\"cit-jnl-abbrev\">Mon Rev<\/abbr> <span>1966<\/span>;<span>18<\/span>:<span>17<\/span>. <a href=\"http:\/\/dx.doi.org\/10.14452\/MR-018-04-1966-08_3\">doi:10.14452\/MR-018-04-1966-08_3<\/a><\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-13-1\" title=\"View reference 13 in text\">13.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>World Health Organization<\/span><\/li>\n<\/ol>\n<cite>. <span>COVAX: Working for global equitable access to COVID-19 vaccines [Internet]<\/span>. Available: <a href=\"https:\/\/www.who.int\/initiatives\/act-accelerator\/covax\">https:\/\/www.who.int\/initiatives\/act-accelerator\/covax<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-14-1\" title=\"View reference 14 in text\">14.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>Gavi, the Vaccine Alliance<\/span><\/li>\n<\/ol>\n<cite>. <span>COVAX Supply Forecast reveals where and when COVID-19 vaccines will be delivered [Internet]<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.gavi.org\/vaccineswork\/covax-supply-forecast-reveals-where-when-covid-19-vaccines-will-be-delivered\">https:\/\/www.gavi.org\/vaccineswork\/covax-supply-forecast-reveals-where-when-covid-19-vaccines-will-be-delivered<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-14-1\" title=\"View reference 15 in text\">15.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>The New York Times<\/span><\/li>\n<\/ol>\n<cite>. <span>Covid-19: How Much Herd Immunity is Enough? [Internet]<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.nytimes.com\/2020\/12\/24\/health\/herd-immunity-covid-coronavirus.html\">https:\/\/www.nytimes.com\/2020\/12\/24\/health\/herd-immunity-covid-coronavirus.html<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-16-1\" title=\"View reference 16 in text\">16.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>BBC News<\/span><\/li>\n<\/ol>\n<cite>. <span>Covid vaccine: UK supply hit by India delivery delay [Internet]<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.bbc.com\/news\/uk-56438629\">https:\/\/www.bbc.com\/news\/uk-56438629<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-16-1\" title=\"View reference 17 in text\">17.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Findlay<\/span> <span>S<\/span><\/span>,<\/li>\n<li><span><span>Peel<\/span> <span>M<\/span><\/span>,<\/li>\n<li><span><span>Mancini<\/span> <span>DP<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>India\u2019s block on vaccine exports deals blow to dozens of nations [Internet]. Financial Times<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.ft.com\/content\/5349389c-8313-41e0-9a67-58274e24a019\">https:\/\/www.ft.com\/content\/5349389c-8313-41e0-9a67-58274e24a019<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-16-1\" title=\"View reference 18 in text\">18.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>BBC News<\/span><\/li>\n<\/ol>\n<cite>. <span>Covid: Italy \u201cblocks\u201d AstraZeneca vaccine shipment to Australia [Internet]<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.bbc.com\/news\/world-europe-56279202\">https:\/\/www.bbc.com\/news\/world-europe-56279202<\/a> [Accessed <span>06 Mar 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-19-1\" title=\"View reference 19 in text\">19.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Nkrumah<\/span> <span>K<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>Neo-Colonialism?: The Last Stage of Imperialism<\/span>. <span>Panaf Books Ltd<\/span>, <span>1987<\/span>.<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-20-1\" title=\"View reference 20 in text\">20.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Safi<\/span> <span>M<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>World Health Organization platform for pharmaceutical firms unused since pandemic began [Internet]. The Guardian<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/www.theguardian.com\/world\/2021\/jan\/22\/who-platform-for-pharmaceutical-firms-unused-since-pandemic-began\">https:\/\/www.theguardian.com\/world\/2021\/jan\/22\/who-platform-for-pharmaceutical-firms-unused-since-pandemic-began<\/a> [Accessed <span>06 Mar 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-21-1\" title=\"View reference 21 in text\">21.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>World Trade Organization<\/span><\/li>\n<\/ol>\n<cite>. <span>Waiver for Certain Provisions of the TRIPS Agreement for the Prevention, Containment, and Treatment of COVID-19 [Internet].<\/span>, <span>2020<\/span>. Available: <a href=\"https:\/\/docs.wto.org\/dol2fe\/Pages\/SS\/directdoc.aspx?filename=q:\/IP\/C\/W669.pdf&amp;Open=True\">https:\/\/docs.wto.org\/dol2fe\/Pages\/SS\/directdoc.aspx?filename=q:\/IP\/C\/W669.pdf&amp;Open=True<\/a> [Accessed <span>06 Mar 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-22-1\" title=\"View reference 22 in text\">22.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>M\u00e9decins Sans Fronti\u00e8res Access Campaign<\/span><\/li>\n<\/ol>\n<cite>. <span>WTO COVID-19 TRIPS Waiver Proposal: Myths, realities and an opportunity for governments to protect access to medical tools in a pandemic [Internet]<\/span>, <span>2020<\/span>. Available: <a href=\"https:\/\/msfaccess.org\/wto-covid-19-trips-waiver-proposal-myths-realities-and-opportunity-governments-protect-access\">https:\/\/msfaccess.org\/wto-covid-19-trips-waiver-proposal-myths-realities-and-opportunity-governments-protect-access<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-22-1\" title=\"View reference 23 in text\">23.?<\/a>\n<div>\n<div><cite><span>The People\u2019s Vaccine [Internet]<\/span>, <span>2020<\/span>. Available: <a href=\"https:\/\/peoplesvaccine.org\/\">https:\/\/peoplesvaccine.org\/<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-24-1\" title=\"View reference 24 in text\">24.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>The Editorial Board<\/span><\/li>\n<\/ol>\n<cite>. <span>A Global Covid Vaccine Heist [Internet].Wall Street Journal<\/span>, <span>2020<\/span>. Available: <a href=\"https:\/\/www.wsj.com\/articles\/a-global-covid-vaccine-heist-11605829343\">https:\/\/www.wsj.com\/articles\/a-global-covid-vaccine-heist-11605829343<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-25-1\" title=\"View reference 25 in text\">25.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Kavanagh<\/span> <span>MM<\/span><\/span>,<\/li>\n<li><span><span>Pillinger<\/span> <span>M<\/span><\/span>,<\/li>\n<li><span><span>Singh<\/span> <span>R<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>To Democratize Vaccine Access, Democratize Production. [Internet]. Foreign Policy<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/foreignpolicy.com\/2021\/03\/01\/to-democratize-vaccine-access-democratize-production\/\">https:\/\/foreignpolicy.com\/2021\/03\/01\/to-democratize-vaccine-access-democratize-production\/<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-26-1\" title=\"View reference 26 in text\">26.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>WTO Analytical Index<\/span><\/li>\n<\/ol>\n<cite>. <span>TRIPS agreement article 31: other use without authorization of the right holder<\/span>, <span>2006<\/span>.<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-27-1\" title=\"View reference 27 in text\">27.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Hannah<\/span> <span>E<\/span><\/span>,<\/li>\n<li><span><span>Scott<\/span> <span>J<\/span><\/span>,<\/li>\n<li><span><span>Trommer<\/span> <span>S<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>The global approach to vaccine equity is failing: additional steps that would help [Internet]. The Conversation<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/theconversation.com\/the-global-approach-to-vaccine-equity-is-failing-additional-steps-that-would-help-158711\">https:\/\/theconversation.com\/the-global-approach-to-vaccine-equity-is-failing-additional-steps-that-would-help-158711<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-27-1\" title=\"View reference 28 in text\">28.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Son<\/span> <span>K-B<\/span><\/span>,<\/li>\n<li><span><span>Lee<\/span> <span>T-J<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>Compulsory licensing of pharmaceuticals reconsidered: current situation and implications for access to medicines<\/span>. <abbr class=\"cit-jnl-abbrev\">Glob Public Health<\/abbr> <span>2018<\/span>;<span>13<\/span>:<span>1430<\/span>\u2013<span>40<\/span>.<a href=\"http:\/\/dx.doi.org\/10.1080\/17441692.2017.1407811\">doi:10.1080\/17441692.2017.1407811<\/a><span><span>pmid:<\/span>http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29183271<\/span><\/cite><\/div>\n<div><a href=\"https:\/\/justpaste.it\/%7Bopenurl%7D?query=rft.jtitle%253DGlob%2BPublic%2BHealth%26rft.volume%253D13%26rft.spage%253D1430%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\"><span>OpenUrl<\/span><\/a><a href=\"https:\/\/justpaste.it\/lookup\/external-ref?access_num=http:\/\/www.n&amp;link_type=MED&amp;atom=%2Fbmjgh%2F6%2F6%2Fe006504.atom\"><span>PubMed<\/span><\/a><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-29-1\" title=\"View reference 29 in text\">29.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Irwin<\/span> <span>A<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>What it will take to vaccinate the world against COVID-19<\/span>. <abbr class=\"cit-jnl-abbrev\">Nature<\/abbr> <span>2021<\/span>;<span>592<\/span>:<span>176<\/span>\u2013<span>8<\/span>.<a href=\"http:\/\/dx.doi.org\/10.1038\/d41586-021-00727-3\">doi:10.1038\/d41586-021-00727-3<\/a><span><span>pmid:<\/span>http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33767468<\/span><\/cite><\/div>\n<div><a href=\"https:\/\/justpaste.it\/%7Bopenurl%7D?query=rft.jtitle%253DNature%26rft.volume%253D592%26rft.spage%253D176%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\"><span>OpenUrl<\/span><\/a><a href=\"https:\/\/justpaste.it\/lookup\/external-ref?access_num=http:\/\/www.n&amp;link_type=MED&amp;atom=%2Fbmjgh%2F6%2F6%2Fe006504.atom\"><span>PubMed<\/span><\/a><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-30-1\" title=\"View reference 30 in text\">30.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>World Health Organization<\/span><\/li>\n<\/ol>\n<cite>. <span>Establishment of a COVID-19 mRNA vaccine technology transfer hub to scale up global manufacturing [Internet]<\/span>. Available: <a href=\"https:\/\/www.who.int\/news-room\/articles-detail\/establishment-of-a-covid-19-mrna-vaccine-technology-transfer-hub-to-scale-up-global-manufacturing\">https:\/\/www.who.int\/news-room\/articles-detail\/establishment-of-a-covid-19-mrna-vaccine-technology-transfer-hub-to-scale-up-global-manufacturing<\/a> [Accessed <span>22 Apr 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-30-1\" title=\"View reference 31 in text\">31.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span>Africa CDC<\/span><\/li>\n<\/ol>\n<cite>. <span>African Union and Africa CDC launches Partnerships for African Vaccine Manufacturing (PAVM), framework to achieve it and signs 2 MoUs [Internet]<\/span>, <span>2021<\/span>. Available: <a href=\"https:\/\/africacdc.org\/news-item\/african-union-and-africa-cdc-launches-partnerships-for-african-vaccine-manufacturing-pavm-framework-to-achieve-it-and-signs-2-mous\/\">https:\/\/africacdc.org\/news-item\/african-union-and-africa-cdc-launches-partnerships-for-african-vaccine-manufacturing-pavm-framework-to-achieve-it-and-signs-2-mous\/<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-32-1\" title=\"View reference 32 in text\">32.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Hickel<\/span> <span>J<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>The Divide: A Brief Guide to Global Inequality and its Solutions [Internet]. Windmill<\/span>, <span>2018<\/span>. Available: <a href=\"https:\/\/www.penguin.co.uk\/books\/111\/1113531\/the-divide\/9781786090034.html\">https:\/\/www.penguin.co.uk\/books\/111\/1113531\/the-divide\/9781786090034.html<\/a> [Accessed <span>31 May 2021<\/span>].<\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-33-1\" title=\"View reference 33 in text\">33.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Grosfoguel<\/span> <span>R<\/span><\/span><\/li>\n<\/ol>\n<cite>. <span>Decolonizing post-colonial studies and paradigms of political economy: Transmodernity, Decolonial thinking, and global coloniality<\/span>. <abbr class=\"cit-jnl-abbrev\">Transmodernity J Peripher Cult Prod Luso-Hispanic World<\/abbr> <span>2011<\/span>;<span>1<\/span>.<a href=\"http:\/\/dx.doi.org\/10.5070\/T411000004\">doi:10.5070\/T411000004<\/a><\/cite><\/div>\n<div><\/div>\n<\/div>\n<\/li>\n<li><a href=\"#xref-ref-34-1\" title=\"View reference 34 in text\">34.?<\/a>\n<div>\n<div>\n<ol class=\"cit-auth-list\">\n<li><span><span>Abimbola<\/span> <span>S<\/span><\/span>,<\/li>\n<li><span><span>Asthana<\/span> <span>S<\/span><\/span>,<\/li>\n<li><span><span>Montenegro<\/span> <span>C<\/span><\/span>, <span>et al<\/span><\/li>\n<\/ol>\n<cite>. <span>Addressing power asymmetries in global health: imperatives in the wake of the COVID-19 pandemic<\/span>. <abbr class=\"cit-jnl-abbrev\">PLoS Med<\/abbr> <span>2021<\/span>;<span>18<\/span>:<span>e1003604<\/span>. <a href=\"http:\/\/dx.doi.org\/10.1371\/journal.pmed.1003604\">doi:10.1371\/journal.pmed.1003604<\/a><span><span>pmid:<\/span>http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33886540<\/span><\/cite><\/div>\n<div><a href=\"https:\/\/justpaste.it\/%7Bopenurl%7D?query=rft.jtitle%253DPLoS%2BMed%26rft.volume%253D18%26rft.spage%253De1003604%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\"><span>OpenUrl<\/span><\/a><a href=\"https:\/\/justpaste.it\/lookup\/external-ref?access_num=http:\/\/www.n&amp;link_type=MED&amp;atom=%2Fbmjgh%2F6%2F6%2Fe006504.atom\"><span>PubMed<\/span><\/a><\/div>\n<\/div>\n<\/li>\n<\/ol>\n<\/div>\n<span><\/span><\/div>\n<span><\/span><\/div>\n<div>I<strong>nformations sur le droit d&rsquo;auteur :<\/strong> \u00a9 Auteur(s) (ou leur(s) employeur(s)) 2021. R\u00e9utilisation autoris\u00e9e sous CC BY-NC. Pas de r\u00e9utilisation commerciale. Voir droits et autorisations. Publi\u00e9 par le BMJ. http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/<br>Il s&rsquo;agit d&rsquo;un article en libre acc\u00e8s distribu\u00e9 conform\u00e9ment \u00e0 la licence Creative Commons Attribution Non Commerciale (CC BY-NC 4.0), qui permet \u00e0 d&rsquo;autres de distribuer, remixer, adapter, construire sur cette \u0153uvre de mani\u00e8re non commerciale, et d&rsquo;accorder une licence \u00e0 leurs \u0153uvres d\u00e9riv\u00e9es selon des conditions diff\u00e9rentes, \u00e0 condition que l&rsquo;\u0153uvre originale soit correctement cit\u00e9e, que le cr\u00e9dit appropri\u00e9 soit accord\u00e9, que les modifications apport\u00e9es soient indiqu\u00e9es et que l&rsquo;utilisation soit non commerciale. Voir : http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.<\/div>\n<div>\n<div>\n<div>\n<div>\n<div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div><\/div>\n<div><\/div>\n<\/div>\n<\/div>\n<div>\n<div>\n<p><\/p>\n<\/div>\n<\/div>\n<div>\n<div>\n<div>\n<div>\n<div>\n<div>\n<div>\n<div>\n<div>\n<div>\n<div>\n<div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>Views: 202<\/p>","protected":false},"excerpt":{"rendered":"<p>Ce billet est une traduction libre d&rsquo;un \u00e9ditorial du British Journal of Medicine sur l&rsquo;\u00e9quit\u00e9 mondiale dans l&rsquo;acc\u00e8s \u00e0 la vaccination contre le Covid 19.&nbsp; L&rsquo;\u00e9quit\u00e9 mondiale en mati\u00e8re de vaccins exige une justice r\u00e9paratrice &#8211; pas de la charit\u00e9&nbsp; Sophie Harman1, Parsa Erfani2,3, Tinashe Goronga4, Jason Hickel5, Michelle Morse2,6,7, Eugene T Richardson2,6 1Politics and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[74],"tags":[384,379,380,378,383,313,382,381,312,370,369],"class_list":["post-1029","post","type-post","status-publish","format-standard","hentry","category-analyses-diverses","tag-aide-au-developpement","tag-bmj","tag-brevet","tag-colonialisme-vaccinal","tag-covax","tag-covid-19","tag-laboratoires-pharmaceutiques","tag-propriete-intellectuel","tag-sars-cov2","tag-strategie-vaccinale","tag-vaccin"],"_links":{"self":[{"href":"https:\/\/debian-economist.eu\/wp\/index.php?rest_route=\/wp\/v2\/posts\/1029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/debian-economist.eu\/wp\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/debian-economist.eu\/wp\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/debian-economist.eu\/wp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/debian-economist.eu\/wp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1029"}],"version-history":[{"count":5,"href":"https:\/\/debian-economist.eu\/wp\/index.php?rest_route=\/wp\/v2\/posts\/1029\/revisions"}],"predecessor-version":[{"id":1035,"href":"https:\/\/debian-economist.eu\/wp\/index.php?rest_route=\/wp\/v2\/posts\/1029\/revisions\/1035"}],"wp:attachment":[{"href":"https:\/\/debian-economist.eu\/wp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/debian-economist.eu\/wp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/debian-economist.eu\/wp\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}